https://www.avient.com/sites/default/files/resources/Specialty%2520Inks%2520-%2520BU%2520Overview.pdf
Revolución 842, Zona Industrial
Ventanilla - Callao, Lima - Perú
Phone: +51.1.613.4242
Rutland/Union Ohio Service Center
777-M-N Dearborn Park Lane
Worthington, OH 43085
Phone: +1 614.846.3055
Rutland/Union Warehouse
28 Eldon Way
Paddock Wood
Kent TN12 6BE UK
Phone: +44.0.1892.834.555
Rutland/Union/Wilflex
Manufacturing Plant
No. 1 QiHang Industrial Park
HaoXiang Road, Shajing Town,
BaoAn District
Shenzhen, China, 518104
Phone: +86.755.2969.2888
Specialty Inks
https://www.avient.com/sites/default/files/2023-03/Syncure XLPE Product Bulletin.pdf
This literature shall NOT operate as permission, recommendation, or inducement to practice any patented invention without permission of the patent owner.
1.844.4AVIENT
www.avient.com
TEST STANDARD UNIT SYNCURE™ XLPE
S1054A ROHS NATURAL
Specific Gravity ASTM D1505 – 0.919
Melt Flow Index, 190°C/2.16kg ASTM D1238 g/10min 1.045
Tensile Strength at Break ASTM D638 psi 2500
Tensile Elongation at Break ASTM D638 % 450
Delta Torque Internal g-m 2154
Moisture Content ASTM D2974 % 0.0004
Gel Content ASTM D2765 % 73
Hot Creep Elongation UL 2556 % 49
Hot Deformation UL 2556 % 6
TECHNICAL PROPERTIES
*Gel Content, Hot Creep Elongation and Hot Deformation measured on 95 phr S1054A / 5 phr S100B system, and cured by autoclave for 9 hours
https://www.avient.com/sites/default/files/2022-05/Compensation Committee Charter (REV 10-2019).pdf
Review and approve (a) attainment levels under the Company’s annual incentive plan; (b)
payments to executive officers of the Company under the annual incentive plan; and (c)
payments to officers, senior managers and employees of the Company under the
Company’s long-term incentive compensation plans
With the assistance of management and any outside advisers the Committee deems
appropriate (a) review and discuss with management the Company’s disclosures in the
CD&A, and, based on this review, make a recommendation as to whether to include it in the
Company’s annual report on Form 10-K and proxy statement relating to the Company’s
annual meeting of shareholders, and (b) prepare a Compensation Committee Report for
inclusion in the Company’s proxy statement or other applicable SEC filings.
4
Board Reports and Annual Evaluation
https://www.avient.com/sites/default/files/2023-03/Silcosperse Flame Retardant Additives Product Bulletin %281%29.pdf
MATERIAL PROPERTY SILCOSPERSE FR
107443
SILCOSPERSE FR
HS 107449
SILCOSPERSE FR
HS-B 107453
Silicone X X X
Ceramifier
Material ceramifies, it doesn’t char.
https://www.avient.com/sites/default/files/2023-12/Cesa Light Additives for Injection Molding Product Bulletin.pdf
Samples containing Cesa Light Additives
(CC01, CC02, CC03) showed limited Delta b (Db)
variations, while the non-UV stabilized sample
showed a high Db variation and visual yellowing.
https://www.avient.com/sites/default/files/2020-09/pei-masterbatch-product-bulletin.pdf
Color specifications are controlled
using the L,a,b color system.
https://www.avient.com/sites/default/files/2022-02/Additives and Colorants for PP-R Pipe Systems Application Bulletin.pdf
Our
solutions help pipe manufacturers comply with DIN
4102 (B1) or Euroclass B - s1 d0.
https://www.avient.com/sites/default/files/2020-08/colormatrix-amosorb-low-haze-product-bulletin-8.5x11.pdf
Compared to previous grades of
Amosorb, 4020G halves the b* color shift resulting
in lower impact on quality of rPET.
https://www.avient.com/sites/default/files/2021-10/remafin-ep-white-masterbatches-for-pharma-application-bulletin_0.pdf
Avient products have not been designed for nor are they promoted or intended for use in:
(a) medical devices categorized by either the United States Food and Drug Administration (FDA) or the International Standards Organization (ISO) as an “implant” device; or “Permanent” as defined under
US Pharmacopoeia (USP) or ISO standards; or
(b) active implantable medical devices as defined in EU Directive 90/385/EEC as amended; or
(c) medical devices for “Long Term” use as defined in EU Directive 93/42/EEC as amended.
https://www.avient.com/sites/default/files/2022-04/MEVOPUR LQ for Silicone Elastomers.pdf
Avient products have not been designed for nor are they promoted or intended for use in:
(a) medical devices categorized by either the United States Food and Drug Administration (FDA) or the International Standards Organization (ISO) as an “implant” device; or “Permanent” as defined under
US Pharmacopoeia (USP) or ISO standards; or
(b) active implantable medical devices as defined in EU Directive 90/385/EEC as amended; or
(c) medical devices for “Long Term” use as defined in EU Directive 93/42/EEC as amended.